A listed North American company needed support with the identification, assessment and in-licensing of early-stage oncology assets.
We consulted our industry network and contacts and identified a number of high-quality opportunities that had not yet been analyzed by our client’s in-house business development team.
We’re working closely with our client’s scientific staff to screen and assess opportunities before entering heads of terms. We’re also giving advice on structuring heads of terms, due diligence and license negotiations.